PD-L1 Expression in Triple-Negative Breast Cancer

Cancer immunology research - United States
doi 10.1158/2326-6066.cir-13-0127
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

7. PD-L1 in Triple Negative Breast Cancer – Optimal Testing for Therapeutic Efficacy

Pathology
Forensic MedicinePathology
2020English

The Association of Genomic Lesions and PD-1/PD-L1 Expression in Resected Triple-Negative Breast Cancers

Breast Cancer Research
Cancer ResearchOncology
2018English

NPM1 Upregulates the Transcription of PD-L1 and Suppresses T Cell Activity in Triple-Negative Breast Cancer

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2020English

Triple-Negative Breast Cancer

2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

MicroRNAs Expression in Triple Negative vs Non Triple Negative Breast Cancer in Tunisia: Interaction With Clinical Outcome

PLoS ONE
Multidisciplinary
2014English

Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Tumor Tissue microRNA Expression in Association With Triple-Negative Breast Cancer Outcomes

Breast Cancer Research and Treatment
Cancer ResearchOncology
2015English

DNA Methyltransferase Expression in Triple-Negative Breast Cancer Predicts Sensitivity to Decitabine

Journal of Clinical Investigation
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy